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Primary cutaneous B-cell lymphomas.
Current concepts. I.
Non-Hodgkin’s lymphomas are a het-erogeneous group of tumors thatarise from the lymphoreticular sys-
tem. Approximately 27% of non-Hodgkin’s
lymphomas occur in extranodal sites, and the
skin is the second most common site of
extranodal involvement (18%) after the gas-
trointestinal tract.1 While in the past
decades, a body of knowledge has been col-
lected on the clinicopathologic profile, clin-
ical course and treatment of many entities
belonging to the group of cutaneous T-cell
lymphomas, our understanding of primary
cutaneous B-cell lymphomas (pCBCL) has
lagged behind. In fact, studies on series of
patients published before 1987 did not dis-
tinguish between primary and second-
ary/concurrent cutaneous presentations of
B-cell lymphoma;2-6 this lack of precision was
based upon the common opinion that cuta-
neous lymphomas other than mycosis fun-
goides mainly represented dissemination
from a nodal disease. On the other hand,
cutaneous B-cell disorders clinically charac-
terized by non-aggressive behavior, excellent
response to local treatments, and a good
prognosis, and histologically showing a top
heavy distribution of the infiltrate, bland
morphology with cytological polymorphism
(small and large cells), and reactive lymphoid
follicles were constantly regarded as reac-
tive processes (B-cell pseudolymphomas,
BCPL).7-11 Studies of large series of patients,
selected on the basis of primary cutaneous
presentation of the disease, no evidence of
extracutaneous spread, and clonality of neo-
plastic B-cells,12-15 documented that pCBCL
are indeed a distinct and peculiar group of
lymphoproliferative disorders that must be
distinguished from non-Hodgkin’s B-cell
lymphomas with secondary cutaneous
involvement and from cutaneous BCPL.
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Background. Primary cutaneous B-cell lymphoma (pCBCL) has only recently been recog-
nized as a distinct clinicopathologic entity. This entity represents a wide spectrum of lym-
phoproliferative disorders that must be separated from non-Hodgkin’s B-cell lymphomas
secondarily involving the skin and cutaneous B-cell pseudolymphomas. They are defined as
B-cell lymphomas originating in the skin, with no evidence of extracutaneous disease at pres-
entation, as assessed by adequate staging procedures.
Information Sources. With the advent of improved immunophenotyping and immuno-
genotyping, increasing numbers of pCBCL cases are being diagnosed. However, there is still
confusion regarding the classification, treatment, and prognosis of these patients. The aim
of this paper is to provide the clinician with a concise summary of the diagnosis, course, and
treatment of pCBCL. Currently, the European Organization for Research and Treatment of Can-
cer classification is the most adequate classification scheme, identifying the subtypes of
pCBCL by clinical behavior and histopathologic findings, and allowing a better management
of the patients. 
State of the Art. Based on this classification, the most common subtypes of pCBCL are
follicular center cell lymphoma and marginal zone B-cell lymphoma, indolent lymphomas with
an excellent prognosis (>95% 5-year survival rate in our series). Although local cutaneous
recurrences are observed in about 25% of patients, dissemination to internal organs is rare.
A less common, specific subtype — the so-called large B-cell lymphoma of the leg(s) — gen-
erally has a poorer prognosis, with a 5-year survival rate of approximately 60%. 
Perspectives. As a rule, pCBCL is highly responsive to radiation therapy, which should be
considered the treatment of choice. Polychemotherapy should be restricted to patients with
involvement of several noncontiguous anatomic sites, those refractory or plurirelapsed after
radiotherapy, or those with extracutaneous spread.
Key words: cutaneous B-cell lymphomas. 
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Epidemiology
According to a large body of literature, pCBCL are
less frequent than cutaneous T-cell lymphomas, with
incidence rates varying considerably between Euro-
pean (ranges from 20% to 25% of all primary cuta-
neous lymphomas)16,17 and North American studies
(ranges from 3.2% to 7.7%).18 However, the results of
other investigations19,20 support the evidence that the
recently more confident and reliable diagnosis of pCB-
CL, due to the accuracy of staging procedures and
advances in immunophenotyping and immunogeno-
typing, is the major cause for the increasing incidence
of extranodal non-Hodgkin’s lymphomas. The crude
incidence rate of pCBCL is 0.7 (standardized rate 0.5)
per 100,000 inhabitants per year.19
Etiology/pathogenesis
At present, there are many unanswered questions
concerning the homing of B-cells to the skin and their
predilection to stay localized to the cutis in many
instances. In fact, there still is no consistent informa-
tion concerning the existence of a B-cell arm of the
skin immune system. In the skin, there are no known
equivalents to Peyer’s patches of the intestinal tract or
Waldeyer’s ring of the pharynx. Currently, the only data
concern the demonstration that sweat and sebaceous
glands synthesize the secretory component of dimer-
ic IgA in humans.21 However, it has been speculated
that the cutis and the draining lymph nodes form an
integrated system whereby a lymphoproliferative
response to antigenic stimuli may be elicited in the
skin.15 Therefore, pCBCL could represent the neoplas-
tic amplification of this process and could be consid-
ered skin-associated lymphoid tissue (SALT)-related B-
cell lymphomas.15 In addition, it is thought that the
expression of skin-specific homing receptors by nor-
mal and/or neoplastic B-lymphocytes in specific situ-
ations may explain the preferential circulation to and
the accumulation in the skin of lymphoid B-cells.
Another speculation concerns the possibility that a
combination of etiological factors (infectious,
immunologic, and genetic), may play a role in the
development of pCBCL. Several infectious agents have
been investigated in pCBCL and, in Europe, there is
strong evidence implicating Borrelia burgdorferi. In
fact, B. burgdorferi-specific DNA sequences have been
demonstrated in a significant minority of pCBCL from
European geographical areas with endemic Borrelia
infections.22,23 These findings are not confirmed in stud-
ies from the United States,24 and Asia.25 Recently,
molecular analysis of pCBCL documented intraclonal
diversity with a high degree of somatic mutations;
these data support the hypothesis of an antigen-driv-
en process arising from transformed germinal center
B-cells.26
Diagnosis
The diagnosis of pCBCL is often quite difficult to
make and, given the absence of gold standards, one
must take advantage of all the available diagnostic
tests (histo-and cytomorphology, immunophenotyp-
ing, and genotyping) to arrive at a final decision. A
histopathologic diagnosis must be made with caution
because of the lack of standards for histological or
cytological evaluation. In fact, the histological profile
of the various subtypes of pCBCL can be quite similar.
In addition, there is evidence that seems to suggest
that low-grade pCBCL and cutaneous lymphoid hyper-
plasias/BCPL may be part of a spectrum of lympho-
proliferative disorders with a step-wise progression
from a reactive to a neoplastic state. This can explain
why it is sometimes so difficult to differentiate early
stages of low-grade pCBCL from cutaneous lymphoid
hyperplasias/BCPL.
Classification
There is still controversy regarding the classification
of pCBCL. Currently, there are two options for labeling
these diseases, the EORTC16 and WHO27 schemes, and
each of these classifications has its own shortcom-
ings. However, a major advantage of the EORTC clas-
sification is that it does classify the entities according
to their clinical behavior. In fact, a recent investigation,
which compared the applicability of the EORTC and
WHO classifications, concluded that the EORTC
scheme allows a more precise categorization and bet-
ter management of patients, especially those affected
by pCBCL.17
A first main difference between the EORTC scheme
and the WHO classification lies in the definition of
primary cutaneous follicle center cell lymphoma
(FCCL). According to the EORTC scheme, FCCL is a
broad term encompassing all lymphomas composed of
follicle center cells, usually a mixture of centrocytes
(small and large cleaved follicle center cells) and cen-
troblasts (large non-cleaved follicle center cells with
prominent nucleoli), ranging from the very rare cases
with a centroblastic/centrocytic morphology and a fol-
licular pattern of growth to the more frequent cases
with a diffuse growth pattern and large cell morphol-
ogy. Conversely, according to the WHO classification,
cutaneous follicle center lymphomas have a partially
follicular pattern and/or are composed of cells that
resemble centrocytes (often large) and centroblasts,
and the diffuse follicle center lymphoma (considered
to be a rare type of lymphoma) is defined as a lym-
phoma composed of cells resembling centrocytes, with
a minor component of centroblasts, and an entirely dif-
fuse pattern; both the small and large cell must have
the immunophenotype of follicle center cells (typical-
ly sIg+, CD10+, bcl-2+, bcl-6+). All cases with a large cell
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morphology and (generally) a diffuse growth pattern
are classified as diffuse large B-cell lymphomas.
A second main difference regards the group of large
B-cell lymphomas. In the EORTC scheme, a separate
entity distinct from FCCL, and termed large B-cell lym-
phoma of the leg, is recognized when a B-cell lym-
phoma predominantly composed of large cells, with
centroblastic and/or immunoblastic features, occurs
on the leg(s).
Quite recently, a consensus has been reached
between representatives of the original EORTC and
WHO groups on a new classification of cutaneous lym-
phomas. This new classification, which will be referred
to as the WHO-EORTC classification for cutaneous
lymphomas, will be published in the WHO Blue Book
series at the end of 2004. In the proposed WHO-EORTC
classification three main types of pCBCL are recog-
nized: (i) primary cutaneous marginal zone B-cell lym-
phoma, (ii) primary cutaneous follicle center lym-
phoma, and (iii) primary cutaneous large B-cell lym-
phoma. Histologically, primary cutaneous follicle cen-
ter lymphoma represents a spectrum of disease and
includes lymphomas with follicular, follicular and dif-
fuse, and diffuse patterns of growth. This type of lym-
phoma is mainly defined according to the criteria used
by the EORTC classification for follicle center cell lym-
phoma, with the exception that rare cases with a
monotonous proliferation of centroblasts and
immunoblasts (generally showing bcl-2 positivity) not
localized on the leg are classified as primary cutaneous
large B-cell lymphomas, leg type. This is in agreement
with the results of a recent multicenter study docu-
menting that primary cutaneous large B-cell lym-
phomas with a predominance of round cells have a
more unfavorable prognosis than cases with a pre-
dominance of large cleaved cells.28 Primary cutaneous
large B-cell lymphomas are diffuse lymphomas with a
predominance of large B-cells, in particular centrob-
lasts and immunoblasts. Within this category, primary
cutaneous large B-cell lymphoma of the leg(s) is rec-
ognized as a distinct entity (primary cutaneous large
B-cell lymphoma-leg-type). Primary cutaneous large
B-cell lymphomas with a similar histology and
immunophenotype which occasionally develop at oth-
er sites are recognized as primary cutaneous large B-
cell lymphomas, leg type. In addition, the WHO-EORTC
classification contains a category primary cutaneous
large B-cell lymphomas, other which refers to a het-
erogeneous group of lymphoproliferative disorders
which do not belong to the group of primary cuta-
neous large B-cell lymphomas, leg type, or to the group
of primary cutaneous follicle center lymphomas with
a diffuse large cell histology. This group includes rare
morphological variants of diffuse large B-cell lym-
phoma with an uncommon morphology, such as
anaplastic or plasmablastic subtypes, intravascular
large B-cell lymphoma, or T-cell-rich B-cell lymphoma,
and/or immunophenotype, clinically not yet well-
defined.
In this review, the EORTC classification for cutaneous
lymphomas will be used.16 According to the EORTC
scheme, the large majority of pCBCL have been clas-
sified as FCCL and only a small proportion as immuno-
cytoma/marginal zone B-cell lymphoma (MZL) or large
B-cell lymphoma of the leg.16 In addition two provi-
sional entities (intravascular large B-cell lymphoma
and plasmacytoma) have been included in the EORTC
scheme. The term provisional entity refers to pCBCL
which display typical histological and immunopheno-
typic features but lack a distinctive clinical presenta-
tion or a defined clinical outcome.
Primary cutaneous follicle center cell
lymphoma 
Primary cutaneous FCCL shows a characteristic clin-
ical presentation consisting in localized, erythema-
tous-to-cyanotic, often mammillated, rarely ulcerat-
ed plaques, nodules or tumors of various size fre-
quently surrounded by small papules and slightly infil-
trated, figurate plaques, present for months to many
years before the onset of larger lesions (Figures 1 and
2). The presence of satellite lesions is an important
clue for the early diagnosis of the lymphomatous
process and its clinical distinction from BCPL (Figure
3). If untreated, skin lesions enlarge over years, but
dissemination to extracutaneous sites is very infre-
quent. Skin lesions usually have a regional distribution
(90.6% in our series), preferentially on the trunk
(49.6%) and head and neck area (31.8%) and, to a
lesser degree, on the limbs (9.2%). Only 9.4% of
patients in our series had lesions located in non-con-
tiguous anatomic sites, and presentation with wide-
spread, disseminated lesions was exceedingly rare.
There is no sex predilection (M:F=1:1 in our series) and
elderly patients are the most frequently affected
(mean age at presentation 55 years; median age 58
years; range 22-88 years).
On histological examination, FCCL shows nodular or
diffuse infiltrates, with the epidermis almost always
spared (Figure 4). The histological picture of a given
specimen can be quite variable, and is primarily relat-
ed to the age and growth rate of the skin lesion.15 Small
and early lesions show patchy-nodular infiltrates
located in the upper and mid dermis. The infiltrates are
composed of a mixture of small cells with a cleaved
nucleus, relatively few large cells with either a cleaved
or non-cleaved nucleus, and many reactive T cells. A
follicular pattern of growth or its remnants may occa-
sionally be seen in these lesions. If present, neoplastic
follicles show germinal centers with clusters of neo-
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plastic bcl-6+ follicle center cells enmeshed in a net-
work of CD21+ and/or CD35+ follicular dendritic cells,
are ill-defined, lack starry sky histiocytes, and have a
reduced or absent mantle zone. These lesions are clas-
sified as centroblastic/centrocytic lymphoma in the
updated Kiel classification,29 as follicular center lym-
phoma in the REAL classification,30 and as cutaneous
follicle center lymphoma in the WHO classification.
Reactive follicle centers and/or their remnants may be
observed.
With progression to a tumorous lesions, the lym-
phoid infiltrates involve the entire dermis, and some-
times the subcutis. Both the number and size of the
neoplastic B-cells increase, whereas the number of
tumor-infiltrating T-cells decreases. Old and/or rapid-
ly growing tumors quite often show a monotonous
infiltrate of large cells, most frequently with cleaved
nuclei. Neoplastic follicles are no longer visible except
for occasional scattered CD21+/CD35+ follicular den-
dritic cells. These lesions are classified as one of the
subtypes of centroblastic lymphoma in the updated
Kiel classification, or as diffuse large B-cell lymphoma
in the REAL and WHO classifications. These lesions are
not associated with a more aggressive clinical course
of the disease.15
Tumor cells express B-cell-associated antigens
(CD19, CD20, CD22, CD79a) and show monotypic sIg+
(the lack of detectable sIg is common in tumorous
lesions with large cell histology). However, monoclon-
al light chain expression can be masked by polytypic,
reactive B-cells, especially in early lesions. Primary
cutaneous FCCL consistently expresses bcl-6 while,
unlike nodal and secondary cutaneous follicular lym-
Figure 1. FCCL. Large cyanotic nodule surrounded by
slightly infiltrated erythematous plaques on the right
thigh of a 71-year old woman.
Figure 2. FCCL. Large tumor derived from the coales-
cence of nodules and plaques on the anterior neck of a
64-year old man.
Figure 3. FCCL. Small nodule surrounded by papules and
small plaques on the back of a 56-year old man.
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phoma,31-33 it does not generally express CD10, very
rarely expresses the bcl-2 protein (faint staining), and
is not associated with the t(14;18) translocation.34 In
contrast, recent studies, mainly from the USA, report-
ed the presence of t(14;18) translocation as well as
bcl-2 expression in cases of primary cutaneous FCCL
with a follicular pattern of growth, raising doubts
about the existence of phenotypic/genotypic differ-
ences between nodal/secondary cutaneous follicular
lymphoma and primary cutaneous FCCL.35-38 The expla-
nation of this discrepancy is still lacking. The estimat-
ed 5-year survival is over 95%. Radiotherapy is the
treatment of choice. Multiagent chemotherapy is rec-
ommended in cases of generalized skin lesions and/or
extracutaneous dissemination.
The homogeneous clinical behavior of cases belong-
ing to the FCCL type of cutaneous B-cell lymphoma,
irrespective of the architectural pattern (follicular or
diffuse) and cellular morphology (predominantly small
or large cell), and the absence (in cases classified as
either follicular lymphoma or diffuse large B-cell lym-
phoma, according to the WHO classification) of recur-
rent chromosomal aberrations, such as translocations
affecting IGH, MYC, BCL6 and MALT1 loci,39 frequent-
ly observed in systemic and diffuse large B-cell lym-
phomas of the leg(s) (see below), are very strong argu-
ments in favor of a holistic conception of FCCL, as
advocated by the EORTC classification, and against the
splitting of this entity into at least two subgroups, as
proposed by the WHO classification.
Immunocytoma/marginal zone B-cell
lymphoma
In the EORTC classification, primary cutaneous
immunocytoma/marginal zone B-cell lymphoma (MZL)
is defined as a proliferation of small lymphocytes, lym-
phoplasmacytoid cells, and plasma cells, showing
monotypic cIg on paraffin sections. In the updated Kiel
classification these lymphomas are termed immuno-
cytomas, while in the REAL and WHO classification
Figure 4. FCCL. Patchy-nodular infiltrates with a tendency to confluence, sparing the epidermis, composed of a mix-
ture of numerous centrocytes and a few centroblasts, with a partially follicular pattern. Tumor cells are strongly bcl-
6+ (bottom right). 
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they are classified as extranodal marginal zone B-cell
lymphomas or MALT-type lymphomas.
Clinically, MZL presents with features substantially
overlapping those of FCCL (Figures 5 and 6), even
though some reports emphasize a preferential location
on the extremities (arms and legs).16,40 From the
histopathologic point of view, this type of lymphoma
is characterized by the presence of nodular or diffuse
infiltrates (Figure 7), with the epidermis almost always
spared. The infiltrates are composed of small lympho-
cytes, centrocyte-like cells, and plasma cells admixed
with variable numbers of centroblast-, and immuno-
blast-like cells. The monotypic lymphoplasmacytoid
and/or plasma cells are usually located at the periph-
ery of the infiltrates (Figure 8), as they are in MALT-
type lymphomas unlike the dispersed distribution of
these cells in nodal29 and secondary cutaneous40
immunocytomas. This is an additional reason for the
present preferred definition of this entity as MZL
instead of immunocytoma, as originally proposed by
Rijlaarsdam and co-workers.40 In many cases of MZL,
well-evident reactive follicles may be observed. PAS-
positive intranuclear or intracellular inclusions are fre-
quently seen. Tumor cells are monotypic cIg+, CD79a+,
CD5−, CD10−, bcl−6−, bcl-2+. Borrelia burgdorferi plays
a role in the pathogenesis of some of these lym-
phomas. MZL has an excellent prognosis; the estimat-
ed 5-year survival is over 95%. Radiotherapy is the
treatment of choice.
A recent study documented the presence of a novel
recurrent translocation involving IGH at 14q32 and
MALT1 at 18q21 in about 27% of primary cutaneous
MZL. In addition, 33% of the cases harboring t(14;18)
(q32;q21) showed trisomy 3 and/or 18, suggesting that
this translocation does not occur as the sole genetic
abnormality.41 Conversely, other translocations
Figure 5. MZL. Erythematous nodule surrounded by slight-
ly infiltrated plaques on the scalp of a 36-year old man.
Figure 6. MZL. Large erythematous plaque on the cheek
of a 46-year old woman.
Figure 7. MZL. Nodular infiltrates sparing the epidermis.
Figure 8. MZL. The neoplastic infiltrate is composed of
small lymphocytes, centrocyte-like cells, and plasma cells
admixed with a few centroblast-, and immunoblast-like
cells. Monotypic (positive) plasma cells are mainly locat-
ed at the periphery of the infiltrate.
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observed in gastric MALT lymphomas, such as t(11;18)
(q21;q21), have not been found in primary cutaneous
MZL.
For many years there was intense debate and little
consensus regarding the definition of the term MZL
and the strict criteria for differentiating this tumor
entity from follicular lymphoma in the skin. In fact,
there was evidence that many cases classified as FCCL,
using the EORTC definition, showed histological char-
acteristics of MALT-type lymphomas when evaluated
following the criteria of the WHO scheme.42 Therefore,
emphasizing the heterogeneity of the histological pro-
file of MZL as a typical feature of this type of lym-
phoma, MZL was proposed as an encompassing term
for the very large majority of pCBCL, including over
90% of primary cutaneous FCCL.43 Indeed, in order to
overcome the problem linked to the histologic dis-
tinction of FCCL from MZL, and in light of the close
similarities in clinical presentation and behavior of
FCCL and MZL, it had been proposed to designate these
indolent pCBCL with an encompassing term: skin-
associated lymphoid tissue (SALT)-related B-cell lym-
phomas.44
Recently, however, it has been documented that
immunohistochemistry may furnish valuable help in
distinguishing follicular lymphoma from MZL in the
skin, especially when lesions have a non-follicular pat-
tern of growth.35,45 In fact, neoplastic cells in follicular
lymphoma consistently express bcl-6 and rarely show
CD10 and/or bcl-2 positivity, while tumor cells in MZL
are almost constantly bcl-2+, bcl−6−, CD10−. In addi-
tion, when follicular structures, or their remnants, are
present, immunophenotyping can help in distinguish-
ing reactive follicles (composed of bcl-6+, CD10+, bcl−
2− follicular center cells associated with CD21+ follic-
ular dendritic cells) from follicles colonized by MZL
(composed of a variable mixture of bcl-6+, CD10+, bcl−
2− follicular center cells and bcl−6−, CD10−, bcl−2+ tumor
cells, associated with CD21+ follicular dendritic cells).
Moreover, when a nodular pattern, lacking a distinct
Figure 9. Large B-cell lymphoma of the leg. Large erythematous plaques are located on the left lower leg of a 76-year
old woman (left). The diffuse infiltrate is made up of large cells, with centroblastic and immunoblastic morphology,
without significant numbers of admixed inflammatory cells (center). Tumor cells strongly express the bcl-2 protein
(right).
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germinal center/mantle zone demarcation is observed
in the context of a diffuse pattern of growth, the pres-
ence of bcl-6+, CD10+ neoplastic cells in the intern-
odular areas may help to distinguish between follicu-
lar lymphoma and MZL.
Large B-cell lymphoma of the leg(s)
According to the definition of the EORTC classifica-
tion, primary cutaneous large B-cell lymphoma of the
leg is a lymphoma with a predominance of large B-
cells (centroblasts and immunoblasts) presenting on
and confined to the leg(s) (Figure 9). These lymphomas
predominantly affect elderly patients. Females are
affected more often than males (M:F=1:3-4).46 Patients
present with red or bluish nodules or tumors on
one/both lower legs. Histologically, characteristic find-
ings include diffuse non-epidermotropic infiltrates
predominantly made up of large non-cleaved B-cells,
with variable proportions of centroblast- and immu-
noblast-like cells. There are few if any admixed small
cells and inflammatory cells. More often, the majori-
ty of neoplastic cells have the morphology of large
non-cleaved follicle center cells, and are classified as
one of the subtypes of centroblastic lymphoma in the
updated Kiel classification. A few cases show an
almost pure population of immunoblasts and are clas-
sified as B-immunoblastic lymphoma in the updated
Kiel classification. In the REAL and WHO classification
these lymphomas are classified as diffuse large B-cell
lymphomas. Tumor cells express monotypic sIg and/or
cIg, CD19, CD20, CD22, and CD79a. These lymphomas
generally strongly express the bcl-2 protein, but are
not associated with the interchromosomal t(14;18)
translocation. Bcl-6 is expressed by most cases, where-
as CD10 staining is generally absent.45 In the case of
solitary or localized skin lesions radiotherapy is pre-
ferred; in all other cases multiagent chemotherapy is
recommended.
In the experience of the Dutch Cutaneous Lymphoma
Working Group, the prognosis of these lymphomas is
less favorable (estimated 5-year survival 58%) than
that of morphologically similar large cell lymphomas
Figure 10. Intravascular large B-cell lymphoma. Accumulation of large neoplastic cells within the dermal blood ves-
sels.
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arising on the head and trunk.46 This more aggressive
behavior is still a matter of debate.42,47-49
The results of a European multicenter study on pri-
mary cutaneous large B-cell lymphomas seem to sug-
gest that the round-cell morphology of the nuclei of
tumor cells (R.R.: 8.5; 95% CI: 2.7-27), the location on
the leg(s) (RR: 4.2; 95% CI: 1.5-11.5), and the presence
of multiple skin lesions (RR: 4.2; 95% C.I.: 1.2-15) are
significantly associated with a worse prognosis, and
that these elements should be taken into account for
a more accurate management of patients.28 In a recent
study by the Scotland and Newcastle Lymphoma
Group,50 disease located on the leg(s) was confirmed to
have a poorer prognosis (leg: 67% 5-year disease-spe-
cific survival; upper body: 100% 5-year disease-spe-
cific survival).
Another recent study on primary cutaneous large B-
cell lymphoma of the leg51 documented that all cases
investigated stained for the L-26/CD20cy and CD79a
antigens and expressed the bcl-2, bcl-6, and MUM-
1/IRF4 proteins but were negative for both the
CD10/CALLA and CD138/syndecan-1 antigens. With
respect to molecular analysis, the lymphoma popula-
tion of all these cases carried hypermutation of Ig
genes, and all but 1 case also harbored mutations of
the BCL-6 gene. These results indicate that primary
cutaneous large B-cell lymphoma of the leg has sim-
ilar morphofunctional and molecular profiles to diffuse
large B-cell lymphomas of other sites. As previously
mentioned, this concept is additionally supported by
the results of a very recent study using interphase flu-
orescent in situ hybridization (FISH), with probes for
the IGH, MYC, BCL6 and MALT1 loci, which docu-
mented that about 80% of large B-cell lymphomas of
the leg harbored breakpoints in at least one of these
loci, displaying a pattern of chromosomal transloca-
tions similar to that of their systemic counterparts,
and quite dissimilar to large cell predominant FCCL.39
Indeed, in the skin, diffuse large B-cell lymphoma, as
defined by the WHO classification and including both
large cell predominant FCCL and large B-cell lym-
phoma of the leg, is not a biologically and clinically
meaningful category of lymphoma.
A very recent paper investigated the expression of
polycomb-group (PcG) genes encoding the HPC-
HPH/PRC1 complex in primary nodal and cutaneous
large B-cell lymphomas. This study documented that
primary nodal large B-cell lymphomas, and secondary
cutaneous localizations from such lymphomas, abnor-
mally express the BMI-1, RING1, and HPH1 PcG genes
in cycling neoplastic cells. By contrast, tumor cells in
primary cutaneous large B-cell lymphomas lacked
BMI-1 expression, whereas RING1 was variably detect-
ed. Lack of BMI-1 expression was characteristic for
primary cutaneous large B-cell lymphomas, because
other primary extranodal large B-cell lymphomas orig-
inating from brain, testes, and stomach were BMI-1-
positive. Expression of HPH1 was rarely detected in
primary cutaneous large B-cell lymphomas of the head
or trunk whereas it was abundant in primary cuta-
neous large B-cell lymphomas of the leg(s), which cor-
relates well with this latter’s recognition as a distinct
clinicopathologic entity. Therefore, clinically defined
subclasses of primary large B-cell lymphomas display
site-specific abnormal expression patterns of PcG
genes of the HPC-HPH/PRC1 PcG complex, and some
of these patterns (expression profile of BMI-1) may be
diagnostically relevant. The distinct expression pro-
files of PcG genes results in abnormal formation of
HPC-HPH/PRC1 PcG complexes, and this may con-
tribute to lymphomagenesis and different clinical
behaviors of clinically defined large B-cell lym-
phomas.52
Intravascular large B-cell lymphoma
According to the definition of the EORTC scheme,
intravascular large B-cell lymphoma, formerly consid-
ered as a vascular proliferation and termed malignant
angioendotheliomatosis, is characterized by an accu-
mulation of large neoplastic B-cells within blood ves-
sels. Patients with this lymphoma present with
indurated violaceous patches and plaques, sometimes
reminiscent of panniculitis, generally located on the
legs or the trunk. Histopathologically, dermal and sub-
cutaneous blood vessels are filled and often dilated by
an accumulation of large lymphoid cells, which may
cause vascular occlusion. Occasionally, atypical cells
can be observed in perivascular areas. Neoplastic cells
are CDl9+, CD20+, CD22+, CD79a+, and monotypic sIg+.
The estimated 5-year survival is 50%.16 Multiagent
chemotherapy is the treatment of choice. These lym-
phomas are not listed in the updated Kiel classification
and in the REAL scheme, while in the WHO classifica-
tion they are classified as intravascular large B-cell
lymphoma. Intravascular large B-cell lymphomas gen-
erally affect the central nervous system and the skin
and are characterized by an aggressive clinical course
and poor prognosis; cases with cutaneous lesions only
seem to have a more favorable clinical behavior. In the
forthcoming WHO-EORTC classification, intravascular
large B-cell lymphoma will be included in the catego-
ry primary cutaneous large B-cell lymphoma, other, as
a specific subtype.
Plasmacytoma
According to the definition of the EORTC classifica-
tion, plasmacytoma is an extremely rare type of pCB-
CL characterized by a clonal proliferation of plasma
cells that develops primarily in the skin (extramedullary
plasmacytoma of the skin) without underlying multiple
myeloma. Patients show solitary or multiple, smooth,
dome-shaped red-to-violaceous nodules; there is no
particular site predilection. From the histopathologic
point of view, there is a nodular or diffuse dermal infil-
trate composed of mature plasma cells. Multinucleat-
ed plasma cells and Russel bodies can be documented
at times. If prominent atypia or numerous mitoses are
present, multiple myeloma should be suspected. On
immunophenotyping, tumor cells are monotypic cIg+,
CD38+, and usually CD19− and CD20−. Aberrant reac-
tivity for HMB-45 and cytokeratins has sometimes
been documented. Treatments of choice are radio-
therapy or surgical excision. The prognosis is excellent
with no lymphoma-related death.16 In the updated Kiel
classification and in the REAL scheme, these lym-
phomas are termed plasmacytoma, while in the WHO
classification they are classified as extraosseous plas-
macytoma. Indeed, most cases reported in the litera-
ture more likely represent reactive plasma cell prolif-
erations or immunocytomas/MZL rather than true
plasmacytomas. A workshop organized by the EORTC
Cutaneous Lymphoma Task Force on plasma cell-rich
cutaneous infiltrates (Bilbao, E, November 30th Decem-
ber 1st, 2001) concluded that most if not all cases of
primary plasma cell-rich infiltrate of the skin can prob-
bably be included in the spectrum of MZL or virus/bac-
teria-linked lymphomas. In agreement with these
results, in the forthcoming WHO-EORTC classification,
these disorders will be included in the category of pri-
mary cutaneous marginal zone B-cell lymphomas.
Miscellaneous rares types [EORTC: not listed]
Two additional types of B-cell lymphoma have been
occasionally reported as arising primarily in the skin.
Mantle cell lymphoma is a B-cell lymphoma com-
posed of small-to-medium-sized cells, which closely
resemble cleaved center cells (centrocytes), charac-
terized by expression of CD5 and CD43 antigens and
bcl-2 and cyclin D1 proteins. On clinical examination,
patients present with erythematous plaques or nod-
ules. Almost without exception this type of lymphoma
involves the skin secondarily (for this reason it has not
been included in the EORTC classification).
T-cell-rich B-cell lymphoma is a lately recognized53
subtype of diffuse large B-cell lymphoma which is his-
tologically characterized by a dense infiltrate com-
posed of a minor population of neoplastic B-cells
(immunoreactive for CD20 and CD79a antigens) in a
background of predominant non-neoplastic, polyclon-
al T cells (expressing T-cell markers such as CD3, CD43,
CD45RO). The diagnosis is frequently difficult because
the neoplastic B-cell population may be quite sparse,
and immunohistochemical and molecular analysis to
identify the B-cell origin and clonality of the cells is
mandatory. Only 15 cases of primary cutaneous T-cell-
rich B-cell lymphoma have been reported worldwide.54
Patients usually present plaques and/or nodules on the
head and neck area or the trunk. There is limited and
conflicting information on prognosis. In the forth-
coming WHO-EORTC classification, T-cell-rich B-cell
lymphoma will be included in the category primary
cutaneous large B-cell lymphoma, other.
Conclusions
Primary cutaneous B-cell lymphomas represent a
wide spectrum of lymphoproliferative disorders that
must be separated from non-Hodgkin’s B-cell lym-
phomas secondarily involving the skin and cutaneous
BCPL. Most pCBCL (89.4% in our series of 274
patients) are characterized by a homogeneous clini-
cal presentation (regional extension, 90.6% in our
series) and behavior, with good response to non-
aggressive treatment modalities (mostly local radio-
therapy) and an excellent prognosis (98.5% 5-year
survival in our series), despite a significant risk of
relapse (24.7% in our series).48,49
Classification schemes used for nodal lymphomas
are somewhat inadequate for categorizing primary
cutaneous lymphomas in a clinically useful way,
while the EORTC scheme allows a more precise cat-
egorization and better management of patients
affected by pCBCL. In particular, in the skin, the cat-
egory diffuse large B-cell lymphoma, as defined by
the WHO classification and including both large cell
predominant FCCL and large B-cell lymphoma of the
leg, is not biologically and therapeutically meaning-
ful. Indeed, separation of large cell predominant FCCL
from this group, with its inclusion in the category of
FCCL, as advocated by the EORTC scheme, is not only
clinically correct and useful for the patients because
it prevents them being given unnecessarily aggressive
treatments, but is also representative of different
incidences of genomic imbalances, possibly indicative
of different pathogenetic mechanisms underlying the
development of these lymphomas.
It is to be hoped that the forthcoming WHO-EORTC
classification for cutaneous lymphomas will finally
solve the classification problem. However, at pres-
ent, given that most data on long-term outcome are
based on the EORTC classification, we suggest always
considering where a specific entity fits within the
EORTC scheme before planning the patient’s man-
agement.
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